摘要
目的:探讨尼莫地平治疗蛛网膜下腔出血脑血管痉挛的有效性和安全性。方法:收集2015年1月至2017年1月入院的108例蛛网膜下腔出血脑血管痉挛患者随机分为两组,对照组患者给予常规治疗,尼莫地平组患者则加用尼莫地平,比较两组患者GCS评分、Hunt-Hess分级、GOS评分、BI指数、疾病相关参数与不良反应。结果:尼莫地平组患者治疗后GCS评分组间比较显著性高于对照组,Hunt-Hess分显著性低于对照组;治疗后3个月GOS评分组间比较显著性低于对照组,BI指数显著性高于对照组;治疗后左侧TCD、右侧TCD、血肿量、IL-6、SBP与DBP水平组间比较均显著性低于对照组,差异有统计学意义(P<0.05);两组患者治疗期间药物不良反应发生率与总发生率比较差异无统计学意义(P>0.05)。结论:尼莫地平治疗蛛网膜下腔出血脑血管痉挛的疗效显著,安全性较高,具有借鉴意义。
Objective:To investigate the efficacy and safety of nimodipine in the treatment of cerebral vasospasm caused by subarachnoid hemorrhage.Methods:108 patients with SAH admitted to our hospital from January 2015 to January 2017 were randomly divided into two groups.Patients in the control group were given routine treatment,nimodipine plus nimodipine,The GCS score,Hunt-Hess grade,GOS score,BI index,disease-related parameters and adverse reactions were compared between the two groups.Results:The scores of GCS in the nimodipine group were significantly higher than those in the control group after treatment,and the scores of Hunt-Hess in the nimodipine group were lower than those in the control group.The GOS scores in the 3-month group were significantly lower than those in the control group(P<0.05).After treatment,the left TCD,the right TCD,the amount of hematoma,the levels of IL-6,SBP and DBP in the two groups were significantly lower than those in the control group There was no significant difference between the two groups in the incidence of adverse drug reactions and the overall incidence of treatment(P>0.05).Conclusion:Nimodipine is effective in treating cerebral vasospasm of subarachnoid hemorrhage and has high safety.
作者
刘小军
吴开毅
刘南午
邱观养
邓耀芳
LIU Xiaojun;WU Kaiyi;LIU Nanwu;QIU Guanyang;DENG Yaofang(Hainan West Central Hospital,Hainan Danzhou 571700,China)
出处
《河北医学》
CAS
2018年第3期405-408,共4页
Hebei Medicine
基金
广东省茂名市科技计划项目
(编号:20130330)
关键词
尼莫地平
蛛网膜下腔出血
脑血管痉挛
Nimodipine
Subarachnoid hemorrhage
Cerebral vasospasm
Adverse reactions
